Retatrutide: Results, FDA Status and Why You Can't Buy It Yet (2026)
Retatrutide is not FDA-approved. Eli Lilly plans to file with the FDA in Q1 2027 after 28.3% average weight loss at 80 weeks in TRIUMPH-1. It is not sold legally in the US.
ℹ We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure
ByGLP1-US Editorial TeamUpdated Trial data from Lilly releases and NEJM; access rules from ClinicalTrials.gov; enforcement from FDA
★ Editor's Choice
Chia Health
4.9Editorial score
Our #1 pick for GLP-1 weight loss online
✓One monthly price: clinician, medication and free shipping included
✓Semaglutide or tirzepatide, as a weekly injection or a daily tablet
✓No insurance needed; HSA/FSA and Klarna accepted
Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure
$212.89first month, then $349/mo
6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.
Lilly has now reported four Phase 3 TRIUMPH trials plus the Phase 2 study in NEJM. Each row shows average body weight lost by dose against placebo, with the trial length and the average pounds lost at the top dose, which is the closest thing to a "before and after" that the data supports.
1 to 12 mg. Avg lost, top dose: not reported in lb
1 to 12 mg
up to 24.2%
2.1%
not reported in lb
TRIUMPH-1 figures use Lilly's efficacy estimand (people who stayed on treatment). On the treatment-regimen estimand, which counts everyone randomized, TRIUMPH-1 results were 17.6% / 23.7% / 25.0% vs 3.9% placebo. At 12 mg, 45.3% of TRIUMPH-1 participants lost 30% or more of body weight (0.5% on placebo).
Retatrutide benefits in trials
In trials · A1C down up to 1.6% (TRIUMPH-2)
In trials · Triglycerides down 37.0% (TRIUMPH-3, 12 mg)
In trials · Systolic BP down 14.0 mmHg (TRIUMPH-4, top dose)
In trials · Knee pain (WOMAC) down up to 75.8% (TRIUMPH-4)
Retatrutide (LY3437943) is an investigational once-weekly injection from Eli Lilly. Semaglutide acts on one hormone receptor and tirzepatide on two. Retatrutide adds a third, glucagon, which researchers think raises energy use rather than only cutting appetite. That is why it gets called "triple G".
GLP-1 receptor
Appetite, fullness
Same target as Wegovy
GIP receptor
Insulin release, tolerability
Shared with Zepbound
Glucagon receptor
Energy expenditure, liver fat
New in retatrutide
Weekly injection
4 to 12 mg studied
Started at 2 mg in trials
GLP-3?
Retatrutide is often searched as "GLP-3". There is no GLP-3 hormone (what GLP-3 means). Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors.
One difference from current drugs showed up in the Phase 2 trial in NEJM: heart rate rose with dose and peaked at week 24, then eased. Lilly will have to show the FDA how that holds up in the larger Phase 3 data. For the basics of how this drug class acts on appetite and blood sugar, see how GLP-1 drugs work.
03 Trial protocols
Retatrutide Doses Studied in Trials
These are research protocols run under medical supervision. There is no approved dose, and no one should dose retatrutide outside a trial.
Target dose in TRIUMPH-1
How participants got there
Steps
4 mg weekly
Started at 2 mg, one step up after 4 weeks
1
9 mg weekly
2 mg, then 4 mg, then 6 mg, raised every 4 weeks
3
12 mg weekly
2 mg, then 4 mg, 6 mg and 9 mg, raised every 4 weeks
4
TRIUMPH-3 and TRIUMPH-4 tested only 9 mg and 12 mg. In the 104-week extension, participants were moved to their maximum tolerated dose of 9 mg or 12 mg. Lilly reported that the 4 mg arm, reached with a single step, had fewer people stop for side effects than placebo (4.1% vs 4.9%).
If you want a dose plan today, it has to be for an approved drug, where the schedule is set by the FDA label and your prescriber. Zepbound starts at 2.5 mg weekly and steps up every 4 weeks. Our Zepbound dosage guide lists every step from the label.
Side effects in the trials were mostly gastrointestinal and rose with dose. TRIUMPH-1 percentages below are the share of participants reporting each event over 80 weeks.
Side effect (TRIUMPH-1)
4 mg
9 mg
12 mg
Placebo
Nausea
28.6%
38.4%
42.4%
14.8%
Diarrhea
25.2%
34.1%
32.0%
13.5%
Constipation
23.8%
25.9%
26.1%
10.9%
Vomiting
10.6%
22.8%
25.3%
4.8%
Dysesthesia (changes in skin sensation)
5.1%
12.3%
12.5%
0.9%
Stopped due to side effects
4.1%
6.9%
11.3%
4.9%
In TRIUMPH-2 (people with type 2 diabetes), the 12 mg arm reported diarrhea in 33.6% and nausea in 28.0%, and dysesthesia in 7.3% (0.7% on placebo). Lilly says dysesthesia events were mostly mild to moderate and most resolved during treatment. Dysesthesia is not a common side effect of semaglutide or tirzepatide, so it is one to watch in the FDA review.
Is retatrutide safe? Under review
Long-term safety is still under FDA review, and no regulator has approved retatrutide for any condition. Products sold online add unknown purity and dose on top of that; a JAMA study of 7,823 Reddit users found increased appetite and fatigue were the top self-reported symptoms. Read more on weight loss peptides side effects and on which weight loss peptides are FDA-approved.
05 Legal access
How to Get Retatrutide Legally (Eli Lilly Early Access)
There are only two legal ways to get retatrutide before approval, and both run through doctors and research sites, not through a website checkout.
1
Join a clinical trial.
Search ClinicalTrials.gov for "retatrutide" and filter by "Recruiting". Trial sites screen you, provide the drug at no cost and monitor you. Many TRIUMPH trials have finished enrolling, so open spots change over time.
2
Lilly pre-approval expanded access (NCT07629401).
Posted June 5, 2026, status "Available". It is narrow. You must be 18 or older, have a BMI of 35+ despite the highest available dose of an approved weight-management drug, have two or more serious obesity-related complications, be unable to join a retatrutide trial, and have discussed all standard options, including bariatric surgery, with your doctor.
3
Your doctor makes the request, not you.
The treating physician contacts the Lilly Answers Center at 1-800-545-5979. Each case also needs FDA and institutional review board (IRB) sign-off.
4
Otherwise, wait for approval.
Lilly plans to file in Q1 2027. Until then, no telehealth clinic, compounding pharmacy or retail pharmacy can legally fill a retatrutide prescription.
Red flags on any retatrutide listing
Risk "Research use only" or "not for human consumption" label next to dosing instructions or influencer codes
Risk No prescription or clinician visit required
Risk Powder in a vial you mix yourself, with unknown purity and dose
Risk Payment by crypto, Zelle or gift card; ships from overseas
Check A US clinic offering "retatrutide": ask for the NDC. There is none.
The FDA states that retatrutide "cannot be used in compounding under federal law" and has not been found safe and effective for any condition. It has warned telehealth companies for marketing retatrutide, ingredient distributors for selling it to compounders, and companies selling it falsely labeled "for research purposes". One example: a March 31, 2026 warning letter to Gram Peptides covered retatrutide and tirzepatide products. Our compounded tirzepatide guide explains what is and is not legal for the approved drugs.
Lilly has not announced a price. Any monthly price you see now is from unapproved sellers, not from Lilly or a pharmacy. Insurance cannot cover a drug that is not approved, and the Medicare GLP-1 Bridge covers only Foundayo, Wegovy and Zepbound KwikPen.
Approved today
What approved options cost, Oct 2026
Zepbound (tirzepatide), Lilly's current obesity drug: $299 to $449/mo self-pay. Zepbound cost
Wegovy pen: $349/mo ($199 for the first 2 fills at 0.25 and 0.5 mg, through Dec 31, 2026); Wegovy HD 7.2 mg $399/mo. Wegovy cost
Retatrutide Release Date and FDA Approval Status 2026
Retatrutide has no release date. Here is what has happened and what comes next. Beyond obesity, Lilly is also testing it in kidney disease: see the TRANSCEND-CKD results.
Dec 11, 2025TRIUMPH-4 readoutDone
28.7% at 68 wk in knee osteoarthritis (12 mg)
May 21, 2026TRIUMPH-1 readoutDone
28.3% at 80 wk (12 mg); 30.3% at 104 wk in the BMI 35+ extension
Jun 5, 2026Expanded access program postedDone
NCT07629401, status "Available", doctor requests only
Jul 23, 2026TRIUMPH-2 and 3 toplineDone
Both positive; filing moved from end of 2026 for manufacturing data
Sep 29, 2026TRIUMPH-2 full dataDone
Up to 20.8% in type 2 diabetes at 80 wk
Nov 2026TRIUMPH-5 primary completionNext readout
Head-to-head vs tirzepatide, about 800 adults. NCT06662383, primary completion estimated Nov 2026.
Q1 2027BLA submission to FDAPlanned
Planned by Lilly, not yet filed
Late 2027 to 2028Realistic US availabilityEstimate (ours, not Lilly's)
Only after FDA review and approval
Why not sooner?
Efficacy was not the holdup. In July 2026 Lilly moved the filing from end of 2026 to Q1 2027 to assemble manufacturing and quality-control data. See Lilly's Q2 update on retatrutide timing.
How long does FDA review take?
Under FDA's PDUFA goals, a standard review of a new drug is 10 months after a 60-day filing period, so about 12 months from submission. A priority review is 6 months after filing. A Q1 2027 filing with standard review points to early 2028; launch timing after that is Lilly's call.
Average weight loss at the top dose, treatment-regimen estimand (everyone randomized)
Retatrutide 12 mg, TRIUMPH-1 (80 wk)25.0%
Tirzepatide 15 mg, SURMOUNT-1 (72 wk)20.9%
Semaglutide 2.4 mg, STEP 1 (68 wk)14.9%
All three bars use the treatment-regimen (treatment-policy) estimand from separate trials with different lengths and populations. Not a head-to-head comparison. On the efficacy estimand, the figures are 28.3% for retatrutide and 22.5% for tirzepatide.
The gap is real but smaller than the headline 28.3% vs 20.9% suggests, because those two numbers come from different analyses. Retatrutide also had more people stop for side effects at 12 mg (11.3%). TRIUMPH-5 will give the first direct answer. For most people starting now, tirzepatide is the closest thing on the market. Full breakdown: retatrutide vs tirzepatide, and for clinics that prescribe it, best GLP-1 providers 2026.
10 FAQ
Retatrutide FAQ
Is retatrutide FDA approved?
No. As of October 2026 retatrutide is an investigational drug. Eli Lilly has finished the TRIUMPH-1, 2, 3 and 4 Phase 3 readouts and plans to submit its biologics license application (BLA) in the first quarter of 2027. Until the FDA reviews and approves that application, no US doctor or pharmacy can legally dispense it outside a clinical trial or Lilly's expanded access program.
What is the retatrutide FDA approval status in 2026?
Not approved and not yet filed. In 2026 Lilly reported TRIUMPH-1 in May (28.3% at 80 weeks), TRIUMPH-2 and 3 topline in July, and full TRIUMPH-2 data in September (up to 20.8% in type 2 diabetes). In July it moved the FDA filing from end of 2026 to Q1 2027 to add manufacturing and quality-control data.
What is the retatrutide release date?
There is none yet. Lilly plans to file in Q1 2027. FDA's PDUFA goal for a standard review of a new drug is about 12 months from submission, or about 8 months with priority review. That points to a realistic US launch in late 2027 at the earliest and more likely 2028. This is our estimate, not a date Lilly has given.
How to get retatrutide?
Only two ways are legal. You can join a clinical trial listed on ClinicalTrials.gov. Or, if you are 18+, have a BMI of 35+ despite the highest available dose of an approved drug, two or more serious obesity-related complications and no access to a trial, your doctor can ask Lilly's expanded access program (NCT07629401) through the Lilly Answers Center at 1-800-545-5979.
What are retatrutide side effects?
Mostly gastrointestinal. In TRIUMPH-1 at 12 mg, nausea affected 42.4% of participants (14.8% on placebo), diarrhea 32.0%, constipation 26.1% and vomiting 25.3%. Dysesthesia, a change in skin sensation, appeared in 12.5% on 12 mg vs 0.9% on placebo; Lilly says most cases were mild to moderate and resolved. Stopping for side effects was 11.3% on 12 mg vs 4.9% on placebo.
Is retatrutide safe?
Not proven yet. Lilly has not filed with the FDA, so no regulator has reviewed the full data. In trials, side effects were mostly GI, and up to 11.3% of people on 12 mg stopped because of them. The Phase 2 study also found a dose-related rise in heart rate that peaked at week 24. Vials sold online as "research" products are unapproved, untested for humans and of unknown content, per the FDA.
How much does retatrutide cost per month?
Lilly has not set a price, and insurance cannot cover an unapproved drug. For reference, Lilly's approved obesity drug Zepbound costs $299 to $449 a month self-pay as of October 2026, and Wegovy costs $349 a month ($399 for Wegovy HD). Any retatrutide price quoted today comes from unapproved sellers, not from Lilly or a pharmacy.
Approved GLP-1 options exist today
Zepbound and Wegovy are FDA-approved now. Talk to a licensed clinician about whether either fits you.
This page is for information only and is not medical advice. Retatrutide is an investigational drug and is not approved by the FDA for any use. Talk to a licensed clinician before starting, stopping or changing any medication.
⚕
Medical Disclaimer: This content is for informational
purposes only and does not constitute medical advice. Always consult a licensed healthcare
provider before starting any medication.
Last updated October 29, 2026. Trial data checked against Lilly releases, NEJM and ClinicalTrials.gov; prices checked October 2026.